Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Hepatocellular carcinoma

What comes after sorafenib?

    • Congress Reports
    • Oncology
    • RX
  • 4 minute read

At the ASCO-GI in San Francisco, hepatocellular carcinoma was one of the focal points. How can therapy be optimized and what are the options for patients who are progressive during or after sorafenib treatment or who cannot tolerate the drug at all? A recent phase III study showed that everolimus did not induce a benefit in overall survival.

(ag) According to Andrew X. Zhu, MD, Boston, the following conclusion can be drawn from the development to date of the multi-kinase inhibitor sorafenib in the treatment of hepatocellular carcinoma (HCC):

  • Moderate efficacy in advanced HCC with so-called Child A cirrhosis.
  • Toxicity and dose management critical
  • Large variability in outcomes depending on geographic region, etiology, and severity of cirrhosis
  • Unknown mechanism of action of sorafenib with respect to clinical benefit and resistance.
  • No valid predictive biomarkers for sorafenib in HCC.

Even after the failure of sorafenib, there is still no effective therapeutic option for advanced HCC. “The Phase III EVOLVE-1 trial now evaluated the efficacy and safety of everolimus in this patient population.”

A total of 546 patients were enrolled in the study, of whom 362 received everolimus (at a dose of 7.5 mg/d) and 184 received placebo. Participants suffered from stage B or C HCC (according to the so-called BCLC classification) at the time of study entry. They were progressive during or after sorafenib treatment (80.8%) or did not tolerate such therapy (19%). The drug in question was administered continuously until progression. In addition, intolerable toxicity was a reason for discontinuation.
Primary Endpoint: Overall survival was determined as the primary endpoint.

Secondary Endpoints: Time to progression, extent of disease control, and safety constituted the secondary endpoints.

Results: Median overall survival was 7.56 months on everolimus and 7.33 months on placebo. Thus, the difference was not significant (p=0.675). Median time to progression was 2.96 months (everolimus) and 2.6 months (placebo), and disease control rates were 56.1% and 45.1%, respectively (p=0.010). The most common grade 3/4 side effects were anemia, asthenia, loss of appetite, and increase in viral hepatitis B load.

“The results show that everolimus cannot improve overall survival in this patient population. The safety profile was consistent with previous studies,” Zhu concluded. “Similarly, another phase III study concluded that brivanib, compared with placebo, also did not significantly improve overall survival in the second-line setting [1]. Furthermore, several other studies failed to demonstrate the superiority of certain agents such as sunitinib, brivanib, and linifanib (tyrosine kinase inhibitors) over sorafenib in the first-line setting. In fact, the safety profile of the compared compounds was mostly worse. In light of these results, research into new molecular agents for the advanced form of HCC becomes all the more important.”

What can we learn from failed studies?

According to Zhu, there are several issues to consider if one wants to learn from the Phase III trials that have failed so far:

  • Phase II data for efficacy assessments need to become more robust.
  • Endpoints such as overall response rate, time to progression, and progression-free survival have their limitations.
  • Safety and tolerability of the tested agents/regimens are important.
  • The clinical and biological heterogeneity of HCC influences the efficacy of targeted therapies.

Promising new active ingredients

Several agents that inhibit pathways of hepatocarcinogenesis are in clinical development:
Antiangiogenic agents: HCC are vascular tumors with elevated levels of the so-called “vascular endothelial growth factor” (VEGF), which is one of the most important factors for liver tumor angiogenesis and is associated with poorer survival. Inhibition of angiogenesis is a potential therapeutic strategy that has long been the subject of intense research in HCC. Currently, for example, pazopanib, lenvatinib, axitinib, and ramucirumab are in clinical development (Table 1).

mTOR inhibitors: While preclinical data show that mTOR inhibitors are effective in inhibiting cell growth and tumor vascularity, everolimus, for example, failed in the Phase III trial mentioned above. However, other mTOR inhibitors such as temsirolimus and sirolimus are also in development.

MET inhibitors: in a phase II study, tivantinib was able to delay progression in second-line patients with HCC compared with placebo, especially in tumors with high MET levels [2]. Therefore, the compound is currently in Phase III.

“Ultimately, there is an urgent need to find new ways of therapy. The failures of some agents in Phase III should not obscure the fact that many new drugs are currently in development and intensive research is being conducted in this area. This raises hope that we are in for further advances in the treatment of HCC,” Zhu concluded his presentation. “However, sorafenib remains the only systemic agent approved for HCC. It’s important that we try to find new pathways of action and use predictive biomarkers and molecular classifications to predict response to each treatment.”

Source: “Advances in the Management of Liver Cancer,” General Session 4 at ASCO-GI – Gastrointestinal Cancers Symposium, January 16-18, 2014, San Francisco.

Literature:

  1. Llovet JM, et al: Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. J Clin Oncol 2013; 31: 3509-3516.
  2. Santoro A, et al: Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63.

InFo Oncology & Hematology 2014; 2(3): 33-34.

Autoren
  • Andreas Grossmann
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • Hepatocellular carcinoma
  • Levantinib
  • Ramucirumab
Previous Article
  • Palliative care and pain therapy

The need for qualified care will grow

  • Education
  • Geriatrics
  • Oncology
  • RX
View Post
Next Article
  • Many cooks spoil the broth

Medication cocktail and dosage card salad

  • News
  • Prevention and health care
  • RX
View Post
You May Also Like
View Post
  • 12 min
  • Liver steatosis with metabolic dysfunction

New nomenclature for non-alcoholic fatty liver disease

    • CME continuing education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • RX
    • Studies
View Post
  • 15 min
  • Diabetes mellitus

Treatment of comorbidities in older people

    • Cardiology
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • RX
View Post
  • 4 min
  • Type 2 diabetes: PAD and diabetic foot syndrome

Prevention is better than cure – don’t miss the risk foot

    • Cardiology
    • Congress Reports
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Geriatrics
    • Prevention and health care
    • RX
View Post
  • 2 min
  • Prostate cancer

High-resolution ultrasound could diagnose prostate cancer faster

    • Congress Reports
    • Oncology
    • RX
    • Studies
    • Urology
View Post
  • 9 min
  • Chronic lung diseases

Sarcopenia and malnutrition in the context of pneumological rehabilitation

    • CME continuing education
    • General Internal Medicine
    • Geriatrics
    • Nutrition
    • Pneumology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 8 min
  • Psychooncology

Communication as the key to therapy adherence

    • CME continuing education
    • General Internal Medicine
    • Practice Management
    • RX
View Post
  • 16 min
  • Blastic plasmacytoid dendritic cell neoplasia

Rare malignancy from a dermatological perspective

    • CME continuing education
    • Dermatology and venereology
    • Genetics
    • Hematology
    • Oncology
    • RX
View Post
  • 4 min
  • From symptom to diagnosis

Lung carcinoma – Pancoast tumor

    • Cases
    • Education
    • Oncology
    • Pneumology
    • Radiology
    • RX
    • Surgery
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Treatment of comorbidities in older people
  • 2
    New nomenclature for non-alcoholic fatty liver disease
  • 3
    Rare malignancy from a dermatological perspective
  • 4
    Communication as the key to therapy adherence
  • 5
    Patience, knowledge and persistence in therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.